Mental Health Patients

David Brulé et al. (2024) · Journal of integrative and complementary medicine

This randomized trial of 146 treated children and adolescents with attention-deficit/hyperactivity disorder (ADHD) explored whether homeopathy helps manage the condition, and which part of the treatment might be responsible. ADHD is a neurodevelopmental condition marked by inattention, hyperactivity and impulsivity, and roughly 30% of diagnosed children do not respond to standard medication or behavioral treatment. Homeopathy uses highly diluted natural substances prescribed one patient at a time, and in practice it combines a long consultation with a chosen remedy. Earlier open-label results could not tell those two components apart, so this study separated them. Children aged 6 to 16 in Toronto, Canada were randomly assigned to one of three groups. One group (47 children) received homeopathic consultations plus an individualized remedy, a second (48 children) received the same consultations plus a look-alike placebo granule, and a third (51 children) continued usual care only. Consultations lasted up to two hours at intake and recurred about monthly for 28 weeks. Parents rated symptoms with the Conners 3 Global Index-Parent T-score, where lower scores mean fewer symptoms. Symptom scores fell by about 6.2 points in the remedy group and 6.4 points in the placebo group, compared with 2.2 points in usual care (complete-case analysis, 126 children). After adjustment, the remedy-plus-consultation group differed from usual care (p=0.037), while the placebo-plus-consultation group fell just short of the corrected significance threshold (p=0.026 against a cutoff of 0.025). The two consultation groups did not differ from each other (p=0.93). A clinically meaningful improvement (a drop of at least 7.36 Conners T-score points) occurred in 35.9%, 44.2% and 13.6% of the three groups respectively (p=0.006). Parents in both consultation groups also reported better coping (p=0.012 and p=0.003). Side effects were all mild (Grade 1), mainly increased hyperactivity, emotional outbursts and tics, and did not differ between groups. Because the remedy and placebo groups improved similarly, the authors attribute the benefit to the consultation rather than the remedy itself. Participants knew whether they were receiving consultations, parents scored the main outcome, and recruitment fell short of the planned 177 because the COVID-19 pandemic halted trials, so expectation effects and limited statistical power remain possible. The authors recommend further research into the mechanism and into whether other forms of consultation or psychological support produce comparable results.

Valérie Dormal et al. (2025) · Nutrients

This randomized, double-blind, placebo-controlled trial with 180 adults in Belgium asked whether two plant extracts, saffron and Chinese skullcap (Scutellaria baicalensis), help people with mild-to-moderate depressive symptoms, alone or together. Saffron's compounds crocin and safranal are thought to keep the brain chemicals norepinephrine, dopamine and serotonin active for longer, a mechanism similar to common antidepressants. Skullcap's flavonoids, mainly baicalin, had shown calming and mood-lifting effects in animal studies, but had never been tested for mood in people. The researchers also wanted to see whether combining the two gave extra benefit. Participants aged 18 to 75, all with a recent depressive episode and Beck Depression Inventory (BDI) scores of 14 to 28, were split into four groups of 42 to 48. For six weeks each person took one capsule every morning: 30 mg saffron extract, 20 mg skullcap extract, both together, or a placebo of 450 mg maltodextrin. Depression was scored with the BDI and the clinician-rated Hamilton scale, anxiety with the STAI-S, and mood and well-being with PANAS, WHO-5 and other short questionnaires at weeks 0, 3, 6 and 8. Everyone improved, including the placebo group: BDI fell significantly in all four groups (p < 0.001), with no difference between them. Differences appeared only in the second half of treatment. Between week 3 and week 6, depression scores kept dropping in the saffron group (-2.4 points, p = 0.036) and combination group (-3.5 points, p = 0.004) but not placebo, and the Hamilton score fell more with saffron than placebo (p = 0.024). Anxiety fell in all three active groups, and well-being (WHO-5) rose more with skullcap and the combination than placebo. Compliance was about 99% in every group, and two weeks after stopping, scores had mostly held steady. The authors attribute the large placebo gains partly to participants being engaged in a study that encouraged them to talk about their problems and act to improve their well-being. Side effects were mostly minor, such as headaches and gastrointestinal complaints. The authors suggest saffron, skullcap and their combination may help mood, and propose a synergistic effect. The strong placebo response, scarce between-group differences, six-week duration, self-report measures and exclusion of severe depression limit how far the results reach. An author works for an ingredient supplier, and whether the findings extend beyond French-speaking adults at one Belgian center is not established. Longer trials, higher doses, severe depression and objective biomarkers such as stress hormones or neurotransmitter levels are recommended for future work, since long-term safety remains unestablished.

Neil P Roberts et al. (2019) · European journal of psychotraumatology

This systematic review and meta-analysis explored which early psychological treatments, started within three months of a traumatic event, reduce post-traumatic stress symptoms. Post-traumatic stress disorder (PTSD) involves intrusive memories, avoidance and heightened alertness that persist after trauma, and acute stress disorder (ASD) is a similar early reaction in the first month. The authors updated an earlier 2009 review, pooled 61 randomized controlled trials, and prepared it as part of the International Society for Traumatic Stress Studies treatment guidelines. Trials were split into three groups: help offered to everyone exposed to a trauma, help for people already showing symptoms, and help for people diagnosed with ASD or PTSD. Included trials tested a wide range of approaches, including trauma-focused cognitive behavioural therapy (CBT-T, which uses written, imagined or real-life exposure to the trauma), cognitive therapy without exposure, brief EMDR (eye movement desensitization and reprocessing, a therapy in which a person recalls a trauma while following guided eye movements), cognitive processing therapy, internet-based self-help and stepped collaborative care. Most participants were adults recruited after accidents, assaults, injury or intensive care. Symptom severity was compared using standardized mean differences (SMD, where negative favors treatment), and the authors rated evidence quality with GRADE. For people not screened for symptoms, no intervention was clinically better than usual care. For people with symptoms, CBT-T outperformed waitlist (SMD -0.63) and supportive counselling (SMD -0.61) after treatment, and the gap was larger in diagnosed ASD or PTSD (SMD -0.89 and -0.75). Cognitive therapy versus waitlist reached SMD -0.68, and brief EMDR reached SMD -2.50, though that result came from four small trials with only 84 participants and very low quality evidence. CBT-T and cognitive therapy performed similarly (SMD -0.19). Benefits were less consistent at 7 to 12 months, and cognitive processing therapy showed no effect in two trials. The authors judged the CBT-T, cognitive therapy and EMDR findings clinically important, whereas significant effects for collaborative care, brief dyadic therapy and a self-guided internet program in unscreened individuals were not judged clinically important. Most ratings were low or very low quality, and few trials reported adverse events. The authors suggest that CBT-T, cognitive therapy and brief EMDR are supported for symptomatic people and that routine intervention for everyone exposed is not supported. They note limits: diverse studies, many small trials, high attrition, inconsistent follow-up and thin safety data. They also caution that the large EMDR effect rests on very few participants, that pooled estimates are uncertain because most GRADE ratings were low or very low, and that non-publication of negative results cannot be excluded.

Lei Yi et al. (2022) · Journal of translational medicine

This randomized controlled trial with 94 women explored whether a 12-week yoga program could ease symptoms of post-traumatic stress disorder (PTSD, a condition marked by intrusive memories, avoidance of reminders, and heightened arousal following a traumatic event) after a motor vehicle accident. All participants had PTSD tied specifically to a car, motorcycle, or pedestrian accident that occurred at least three months earlier. The intervention used Kripalu yoga, a style emphasizing gentle self-observation and the connection between mind and body rather than intensive physical exertion, compared against an active control condition built around social conversation and board games. Ninety-four women were randomly assigned to a yoga group (47) or control group (47); 37 and 39, respectively, completed the trial through a 3-month follow-up. The yoga group attended six 45-minute sessions across 12 weeks, practicing breath awareness, body-focused attention during postures, and tolerance of physical discomfort under a yoga instructor's guidance. The control group met on the same schedule for daily-life conversation and games. Psychological distress was measured with two self-report instruments, the Depression Anxiety Stress Scales (DASS-21) and the Impact of Event Scale-Revised (IES-R), completed at baseline, immediately after the program, and three months later. After the program, the yoga group's total IES-R score, covering intrusion, avoidance, and hyperarousal symptoms, was significantly lower than the control group's (p = 0.01, meaning the difference was unlikely due to chance), with the difference concentrated in intrusion (p = 0.002) and avoidance (p < 0.001) rather than hyperarousal, which did not differ significantly. Intrusion and avoidance remained significantly lower in the yoga group three months later (p = 0.037 and p = 0.005). On the DASS-21, total distress scores were significantly lower in the yoga group both immediately after the program (p = 0.043) and at three-month follow-up (p = 0.024), with depression (p = 0.033, then p = 0.004) and anxiety (p < 0.001, then p = 0.035) each significantly reduced compared with control. The stress subscale of the DASS-21 showed no significant difference between groups at either timepoint. Both groups improved somewhat over time, including the control group, which the authors attribute partly to the social contact built into the comparison condition. The authors describe the results as preliminary evidence that a structured yoga program reduced depression, anxiety, and the intrusion and avoidance symptoms of PTSD in women following a motor vehicle accident, while finding no measurable effect on stress or hyperarousal. The trial enrolled a relatively small, single-site sample of Chinese women, tested only one yoga style, and relied entirely on self-report questionnaires rather than clinician-rated diagnostic measures. The authors point to comparing yoga styles and isolating which specific session components drive symptom change as directions for future research.

Peter J Bayley et al. (2022) · BMJ open

This parallel-group, randomised non-inferiority trial with 85 military veterans explored whether Sudarshan Kriya Yoga (SKY) -- a structured program of breathing exercises (pranayama) and meditation -- works as well as cognitive processing therapy (CPT), a standard trauma-focused psychotherapy, for reducing post-traumatic stress disorder (PTSD) symptoms. PTSD is a condition that can develop after a traumatic event, involving re-experiencing, avoidance, and heightened arousal. A non-inferiority design tests whether a new approach is not meaningfully worse than an established one, rather than whether it is better, which is appropriate when the existing treatment is already known to be effective. Veterans (88% men, average age 57) with elevated PTSD symptom scores were randomly assigned to SKY (n=41) or CPT (n=44) at a Veterans Affairs outpatient clinic. SKY was taught in small groups over a five-day intensive workshop plus ten weekly sessions (25 hours total), combining five distinct breathing techniques with meditation. CPT consisted of twelve individual sessions over six weeks (12 hours), focused on shifting trauma-related thinking patterns. Symptom severity was measured with the PTSD Checklist-Civilian Version (PCL-C), alongside depression (Beck Depression Inventory-II) and mood (Positive and Negative Affect Schedule). Both treatments reduced PTSD symptoms by the end of six weeks (CPT: -6.8 points, effect size d=0.58; SKY: -5.6 points, d=0.41), and the small gap between them (-1.2 points, 95% CI -5.7 to 3.3) fell safely within the study's 10-point margin for calling SKY "not meaningfully worse" -- a pattern that held at 1 month and 1 year. SKY also matched CPT on depression and mood scores through the 1-month mark, though CPT pulled ahead on both by 1 year. Dropout was similar overall (SKY 27% vs CPT 34%), and among veterans who attended at least one session, fewer left SKY (9%) than CPT (29%). Two adverse events occurred in the CPT group (treatment-related distress; a hospital admission for suicidal ideation); none were reported in the SKY group. The authors describe these results as preliminary support for SKY as a non-trauma-focused option for veterans with PTSD symptoms, comparable in the short term to an established first-line therapy. They note SKY involved roughly twice the contact time of CPT, the trial ran at a single site with a moderate sample of 85 participants, and CPT's own effect size was smaller here than in some earlier veteran studies. The authors state that SKY warrants further clinical and research attention.

Poung-Sik Yeon et al. (2022) · International journal of environmental research and public health

This study tested whether a nearby city park forest — not a remote wilderness — could help treat clinically diagnosed depression. Fifty adults aged 20 to 59 with a psychiatrist-confirmed diagnosis of mild depression were split into two groups: one attended a 6-week urban forest therapy program at Seoul Forest, a large accessible park in Seoul, South Korea, while the other continued their usual depression care (medication and/or counseling) without the forest program. Forty-seven people completed the study. The forest group met once a week for two hours over six weeks, doing gentle activities built around the five senses — stretching, mindful forest walking, an emotional card game, and breathing and meditation exercises — following a three-step approach: noticing feelings, breaking negative thought patterns, and building new daily habits. Both groups filled out standard, validated questionnaires before and after the program measuring depression (self-reported and clinician-rated), sleep quality, and physical (somatic) symptoms often tied to depression. The forest therapy group improved significantly on every measure: depression scores, sleep quality, and physical symptoms all got meaningfully better, while the group getting usual care alone showed little to no improvement on most of these. Most strikingly, on the clinician-rated depression scale, the forest group's average score dropped from a level indicating depression down to a score low enough to count as clinical remission — while the usual-care group's scores stayed in the depression range. On the self-reported depression scale, symptoms dropped by about a third, roughly comparable to what published studies find with cognitive behavioral therapy, a standard talk-therapy treatment. These results suggest a simple, once-a-week program in an ordinary city park forest — no remote retreat required — could meaningfully help people with depression, on top of their regular treatment, not instead of it. The study was fairly small, mostly female, and only followed people for six weeks, so it can't say whether the benefits last, and it can't fully separate the effect of the forest setting from simply doing a structured group activity. Still, it points to accessible urban green space as a promising, low-cost tool that could be added to standard depression care.

Nima Javadzade et al. (2024) · BMC public health

This randomized controlled trial with 60 depressed older adults living in nursing homes in Isfahan, Iran, explored whether an 8-week Mindfulness-Based Stress Reduction (MBSR) program could ease depression, improve emotion regulation, and reduce sleep problems. MBSR is a structured group program, originally developed for stress and chronic illness, that trains people to notice thoughts, emotions, and body sensations without judgment through practices like body scanning and gentle movement. Emotion regulation here covers two distinct skills the study measured separately: cognitive reappraisal (reinterpreting a situation to change its emotional impact) and expressive suppression (holding back outward emotional expression), the latter generally considered a less adaptive coping strategy. Participants, referred by geriatricians and screened with the Geriatric Depression Scale, were randomly split into an MBSR group (30 people, average age 66) and a no-treatment control group (30 people, average age 67); 60% of each group were women. The MBSR group attended eight weekly 90-minute sessions with a certified instructor, practicing body scans, mindful movement, loving-kindness meditation, walking meditation, and mindful eating, plus home practice between sessions. Before the program and one week after it ended, both groups completed the Geriatric Depression Scale, the Emotion Regulation Questionnaire, and the Pittsburgh Sleep Quality Index. After 8 weeks, the MBSR group showed significantly lower depression scores than the control group (adjusted averages 6.28 vs. 8.82, p<0.001), with a large effect size (partial eta squared=0.57, meaning the intervention accounted for over half the variance in the outcome). Emotion regulation shifted favorably on both subscales: cognitive reappraisal rose (22.67 vs. 20.36, p<0.001) while expressive suppression fell (12.32 vs. 15.65, p<0.001, partial eta squared=0.56) — a pattern consistent with Gross's emotion regulation model, in which stronger reappraisal skills reshape an emotional response early, reducing reliance on effortful suppression later. Sleep quality also improved, with lower Pittsburgh Sleep Quality Index scores in the MBSR group (11.58 vs. 13.35, p<0.001), which the authors link to MBSR increasing attentional control over the automatic arousal and rumination that disrupt sleep. All four outcomes reached statistical significance with observed power near 1.00 (a near-certain ability to detect a true effect). For nursing-home psychologists and caregivers, MBSR appears to be a practical, side-effect-free complement to standard depression care for older residents, requiring only a certified instructor and a weekly 90-minute time commitment. Limitations are real: outcomes relied entirely on self-report in a population prone to inaccurate self-assessment, the control group received no intervention at all rather than an active comparison, there was no follow-up beyond one week, and the sample was limited to depressed nursing-home residents in Iran. Future research should add objective measures and longer follow-up before these findings are treated as conclusive.

Katarzyna Janda et al. (2020) · Nutrients

This systematic review pooled nine randomised clinical trials to ask whether passionflower (Passiflora incarnata) helps with anxiety, sleep and related neuropsychiatric symptoms. Passionflower is a perennial climbing vine whose aerial parts, flowers and fruit are used medicinally, and whose activity is attributed to flavonoids such as apigenin and luteolin and to flavonoid glycosides including vitexin and isovitexin. The European Medicines Agency recognised it as a medicinal product in a 2014 herbal monograph. The review frames the problem as stress — the body's response to physical and psychological stressors, which becomes pathological when prolonged and can impair concentration and memory. The authors searched PubMed, Embase and ClinicalTrials.gov to October 2019 and screened 417 records down to nine trials run between 2017 and 2019, five of them in Iran. Participants were all adults, between 16 and 128 per trial, and eight of the nine trials enrolled healthy volunteers rather than diagnosed patients. Preparations varied widely — drops, tablets, syrup, a standardised extract and herbal tea — over periods from a single day to 30 days. Anxiety was measured with instruments including the State-Trait Anxiety Inventory and the Corah Dental Anxiety Scale, sedation with the Ramsey scale, and sleep with polysomnography. Most trials found reduced anxiety, though the benefit was smaller in people whose anxiety was mild to begin with. In generalised anxiety disorder, 45 drops daily for 28 days matched oxazepam without impairing work performance. Before surgery, 500 mg tablets lowered anxiety more than oxazepam, and a 700 mg per 5 mL syrup given 30 minutes before spinal anaesthesia reduced anxiety with haemodynamics unchanged. Compared with midazolam before wisdom-tooth extraction, 260 mg gave similar calming with markedly less somnolence (50% versus 82.5%) and no amnesia at all, against 20% on midazolam — although more participants would still choose midazolam again (52% versus 27.5%), which the authors attribute to that same amnesia preventing negative memories. Herbal tea drunk nightly for a week improved self-reported sleep quality by 5.2% over placebo. No adverse effects, memory loss or collapse of psychometric function were reported anywhere in the review. The practical reading is that passionflower performs comparably to two established sedatives for procedural anxiety, with a different side-effect profile — less somnolence, no amnesia — which may matter where alertness is wanted afterwards. The evidence is genuinely limited, though: nine small trials, too heterogeneous to pool statistically, three of them rated low quality, and most never recorded which part of the plant was used. Its anxiolytic action is thought to work through the GABA system. Larger trials across more varied populations are needed before firm dosing guidance is possible.

Sonia Zadro et al. (2022) · Frontiers in psychology

This study aimed to evaluate the effectiveness of Reiki over placebo in treating mental health symptoms, particularly focusing on anxiety, stress, and depression. Given the increasing prevalence of mental health disorders and the economic burden they impose, understanding the efficacy of Reiki could provide a safe and cost-effective treatment option. The findings suggest that Reiki may offer therapeutic benefits, although the overall evidence remains inconclusive due to the limited number of studies and concerns about bias. The study design was a systematic review of randomized controlled trials (RCTs), including a total of 14 studies with participants aged 18 years or older, both healthy and those with mental health conditions. The intervention tested was hands-on Reiki, where practitioners used specific hand positions either touching or near the participants' bodies. Outcomes were measured using standardized mental health outcome measures, including anxiety, depression, and stress, utilizing validated questionnaires and scales. The duration and frequency of Reiki sessions varied across studies, with specific details not provided. Results indicated that Reiki significantly reduced state anxiety in knee replacement patients (p = 0.004, d = 0.93) and caregiver stress levels (p < 0.001, d = 2.3). Additionally, state and trait anxiety in fibromyalgia patients were significantly reduced after four sessions (p = 0.005 and p = 0.003, respectively). However, no significant differences were found in anxiety or depression for participants with normal mental health scores (anxiety p = 0.295; depression p = 0.102). Participants frequently reported feelings of relaxation and reduced stress levels after Reiki sessions, and no adverse effects were reported in any of the studies. The authors concluded that Reiki shows a moderate to high therapeutic effect on mental health symptoms compared to placebo, suggesting it could be integrated into treatment plans for patients experiencing anxiety, stress, and depression. However, the study is limited by the small number of studies, potential biases, and confounding variables affecting outcomes. Future research should focus on well-controlled double-blind experiments to isolate the mechanisms of Reiki and confirm its efficacy, particularly regarding dose-response relationships and long-term effects.

Mahendra Kumar Trivedi et al. (2024) · Health psychology research

This randomized, placebo-controlled, double-blind study provides evidence on the effectiveness of distant biofield energy healing for psychological and mental health-related symptoms. The study involved 114 participants (55 male, 59 female) who exhibited one or more psychological symptoms, such as anxiety, depression, and cognitive impairment. Participants were divided into three groups: a biofield intervention group, a control group, and a sham control group. The biofield intervention group received two sessions of distant energy healing, while the other groups received similar treatments to control for baseline responses. Results indicated that the biofield intervention group experienced significant improvements in psychological symptoms, with a p-value of less than 0.0001, suggesting a strong statistical significance. This means that the improvements observed were unlikely to be due to chance. Participants reported reductions in fatigue, sleep disturbances, anxiety, and emotional trauma, among other symptoms. Importantly, no adverse effects were reported in any of the groups throughout the trial, indicating that the biofield therapy was safe. These findings point to distant biofield energy healing as a possible complementary approach in mental health, on this study's evidence. However, it is essential to note that this study was conducted at a single center with a relatively small sample size, which may limit the generalizability of the results. Future research with larger, more diverse populations is necessary to confirm these findings and explore the mechanisms behind the observed effects. In summary, this study suggests distant biofield energy healing may improve mental health and overall quality of life measures; the authors frame it as a complement to conventional treatment.